Skip to main content
09/01/2024

Combination of antitumor drugs improves survival in patients with an aggressive type of pediatric cancer

Dr. Lucas Moreno

Dr. Lucas Moreno

09/01/2024

The BEACON clinical trial, in which Vall d'Hebron participates, has observed that adding Bevacizumab to treatment with different chemotherapy drugs reduces tumor size in a greater number of patients.

The BEACON clinical trial, in which Vall d'Hebron has participated, has shown that the combination of antitumor drugs in chemotherapy improves the response to treatment and survival in patients with relapsed or refractory neuroblastoma, a very aggressive type of childhood cancer. The results of the study, led by the University of Birmingham, have been published in the Journal of Clinical Oncology.

The study, the largest clinical trial conducted so far in relapsed or refractory neuroblastoma, involved 160 patients between 1 and 21 years of age from 43 hospitals in 11 European countries. Half of them received conventional treatment with chemotherapy, while the second group was additionally administered Bevacizumab. This drug blocks the tumors from forming blood vessels and thus makes it more difficult for them to receive food and oxygen and helps the cancer cells to die.

The results show that, in the group receiving Bevacizumab together with conventional therapy, 26% of patients responded to treatment, i.e. they had a reduction in tumor size. In contrast, in the group receiving standard therapy alone, only 18% of patients responded to treatment. In addition, patients with Bevacizumab had better survival rates after one year, especially with the three-drug combination of Bevacizumab, irinotecan and temozolomide.

"BEACON has helped us to identify new treatment combinations for patients with relapsed neuroblastoma. The results offer new therapeutic options for patients with poor prognosis who until now did not respond to any established treatment", says Dr. Lucas Moreno, international coordinator of the clinical trial and head of the Pediatric Oncology and Hematology Department at Vall d'Hebron University Hospital and of the Childhood Cancer and Blood Disorders group at Vall d'Hebron Research Institute (VHIR).

BEACON study to improve neuroblastoma treatment

BEACON is a Phase II clinical trial aimed at improving the treatment of children and adolescents with relapsed or non-responsive neuroblastoma. The study is the result of collaboration between 43 hospitals in Europe, with the participation of the expert groups SIOPEN (International Society of Paediatric Oncology European Neuroblastoma) and ITCC (Innovative therapies for children with cancer). In Spain, it has the participation of Vall d'Hebron, Hospital Infantil Universitario Niño Jesús, Hospital Universitario La Fe, Hospital de Cruces and Hospital Universitario Virgen del Rocío.

The BEACON2 study is currently underway, which will test new therapeutic combinations to improve the response to treatment and, therefore, the survival and quality of life of children affected by the disease and their families.

The data from the study offer new therapeutic options for children and adolescents with neuroblastoma.

Related news

La iniciativa "Sin Piedad" explica la història d'en David, un nen que s'està tractant d'un càncer pediàtric, un exemple d'actitud lluitadora davant la malaltia.

The money will allow research into paediatric nervous system tumours and childhood sarcomas to continue, with the aim of improving children's chances of survival and reducing the side effects of treatment.

The association makes the fifth annual donation of 52,390€ that will finance a project to study new therapies for this childhood tumor.

Related professionals

Lucas Moreno Martín-Retortillo

Lucas Moreno Martín-Retortillo

Head of group
Childhood Cancer and Blood Disorders
Read more
María de los Ángeles Rodríguez Sánchez

María de los Ángeles Rodríguez Sánchez

Administration and Management
Childhood Cancer and Blood Disorders
Read more
Laura Alonso Garcia

Laura Alonso Garcia

Senior researcher
Childhood Cancer and Blood Disorders
Read more
Claire Diot

Claire Diot

Administration and Management
Childhood Cancer and Blood Disorders
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.